Senzime First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Senzime (STO:SEZI) First Quarter 2024 Results

Key Financial Results

• Revenue: kr12.1m (up 66% from 1Q 2023).
• Net loss: kr27.9m (loss narrowed by 9.3% from 1Q 2023).
• kr0.23 loss per share (improved from kr0.42 loss in 1Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Senzime EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 10%. Earnings per share (EPS) exceeded analyst estimates by 23%.

Looking ahead, revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's shares are up 2.9% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 5 warning signs for Senzime that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.